4 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
4 May 23
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
4:05pm
to a decrease in third-party expenses due to our continued wind down related to the discontinuation of our STOPS and ASO programs, and the manufacturing
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
4 Aug 22
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
4:06pm
in R&D expenses for this comparative period is primarily attributable to our continued wind-down related to the discontinuation of our STOPS and ASO
S-1/A
EX-3.2
ALGS
Aligos Therapeutics Inc
9 Oct 20
IPO registration (amended)
5:26pm
of the then-serving Series A Directors (if any);
3.3.5 liquidate, dissolve or wind-up the business and affairs of the Corporation, effect any merger
S-1
EX-3.1
ALGS
Aligos Therapeutics Inc
25 Sep 20
IPO registration
5:27pm
(if any);
3.3.5 liquidate, dissolve or wind-up the business and affairs of the Corporation, effect any merger or consolidation or any other Deemed
- Prev
- 1
- Next